PACB Stock Performance, Insider Transaction and News

PACB - Pacific Biosciences of Californ

Market Cap	3.13B	P/E	-	EPS this Y	24.80%	Ern Qtrly Grth	-
Income	-296.9M	Forward P/E	-12.52	EPS next Y	19.80%	50D Avg Chg	-5.00%
Sales	200.43M	PEG	2.41	EPS past 5Y	-	200D Avg Chg	17.00%
Dividend	N/A	Price/Book	4.88	EPS next 5Y	-1.00%	52W High Chg	-14.00%
Recommedations	2.40	Quick Ratio	8.12	Shares Outstanding	272.36M	52W Low Chg	162.00%
Insider Own	1.85%	ROA	-10.84%	Shares Float	270.90M	Beta	1.98
Inst Own	94.56%	ROE	-44.28%	Shares Shorted/Prior	52.82M/49.05M	Price	12.52
Gross Margin	30.38%	Profit Margin	-148.13%	Avg. Volume	3,583,696	Target Price	4.67
Oper. Margin	-209.82%	Earnings Date	Jul 31	Volume	6,211,175	Change	-6.15%

Healthcare | Medical Devices | United States

About Pacific Biosciences of Californ

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Pacific Biosciences of Californ News

05/15/24	Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases
05/14/24	Pacific Biosciences to lay off 195 employees as part of cost cuts
05/11/24	Pacific Biosciences of California First Quarter 2024 Earnings: Misses Expectations
05/10/24	Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2024 Earnings Call Transcript
05/10/24	Pacific Biosciences of California Inc (PACB) Q1 2024 Earnings: Narrowing Losses but Misses ...
05/10/24	PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
05/09/24	Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
05/09/24	Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
05/09/24	PacBio Announces First Quarter 2024 Financial Results
05/07/24	Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
05/02/24	Investors Heavily Search Pacific Biosciences of California, Inc. (PACB): Here is What You Need to Know
04/25/24	Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks
04/23/24	Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know
04/18/24	Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 18%
04/17/24	PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
04/16/24	The Cathie Wood Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving
04/16/24	PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
04/03/24	Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
03/27/24	Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
03/22/24	PacBio Grants Equity Incentive Award to New Employee

PACB Chatroom

cchen2783 Posted - 5 hours ago

@DieHard09 great buy is $PACB

KC117 Posted - 7 hours ago

$PACB I was able to offload most of my shares during the recent pump. Now I’m looking to get back in.

2019Bull2025 Posted - 1 day ago

$PACB they are adding ladies , time to add

2019Bull2025 Posted - 1 day ago

$PACB compare my previous post to this

2019Bull2025 Posted - 1 day ago

$PACB Ark holdings after yesterday’s trade K 19, 6550, 039 G 12,192,925 shares

RexColbrook Posted - 1 day ago

$PACB AH volume ?

Keepitmoving Posted - 2 days ago

$BNGO $GME $PACB meme stock. Nerdish should be ashamed to recommend this horribly configured company with soon to be obsolete technology that is current limited to large SV and adjunct runs. Shame on you Nerdish.

AnniyanS Posted - 2 days ago

$PACB Let me repeat...the price will be right at about $0.65. So another 2/3 room for downside. Just sit back and give it a couple of Quarters and you will see what I am talking about. More dilution will also likely happen for mere survival. NFA.

Neubaufahrzeug Posted - 2 days ago

$PACB Told you to sell options.

Nerdish Posted - 2 days ago

$GME Anyone also remember $BNGO ? Was waiting on management to cut costs which have been done. Still waiting on FDA approval. Not heavily shorted. Overall trend is upward since the $.7 low. Short interest will climb if the stock starts to gain interest. Has financing available through High Trails. Still unprofitable but this is speculation season and it’s heavily undervalued with analysts at approximately $5. If that’s not of interest take a look at $PACB They are on solid footing and with Powell/Biden duo dead set on lowering rates the future is only up from here.

strattonoakmont69 Posted - 2 days ago

$FFIE lets run $PACB up before closing 👀

Bidzill Posted - 2 days ago

$PACB They've been trying to cap it at 2.10 since 11:00AM (USA Central Time). Barcoding taking place. Algorithms creating synthetic price action.

klem817 Posted - 2 days ago

$PACB if go lower 2.11 not holds it go 1.5

Bidzill Posted - 2 days ago

$PACB $2.04 key level

matcur Posted - 2 days ago

$PACB typical Friday

Moneyman99 Posted - 2 days ago

$PACB oh I must be blind. Looks headed down to me.

Axxxo Posted - 2 days ago

$PACB

SammyWhammyBammyLammy Posted - 2 days ago

$PACB $GME $AMC JUST FOR CLARIFICATION, THERE IS NO OFFERING. ALSO $GME CEO PUT SPECIFIC LANGUAGE STATING:" Investors with a short exposure may have to pay higher premiums for stock which could result in what is known as a "short squeeze"." IM NOT SELLING MY SHARES

SM07 Posted - 2 days ago

$PACB Will it follow $GME with an offering…? It should!

CebuCity Posted - 2 days ago

$PACB Hey thanks for the make believe analysis.....now FO...Thanks

CebuCity Posted - 2 days ago

$PACB Finnaly trimming the fat...long time coming that should have been done 3-6 months ago....hopefully the CEO will get off his azz and get more involved in selling....

SeeTheFuture Posted - 3 days ago

$PACB Shorts getting burnt real bad here soon! Flame on!!! Let's burn some shorts before the weekend!

manojaggarwal Posted - 3 days ago

$PACB this is going to run like $GWAV soon

JasonLg Posted - 3 days ago

$PACB Heading UP to fill the GAP (top purple line)

Bidzill Posted - 3 days ago

$PACB I'd consider this a breakout...

RexColbrook Posted - 3 days ago

$PACB 💎 Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$193.1m to US$186.5m. 2024 losses expected to reduce from -US$1.04 to -US$0.928 per share. Life Sciences industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$5.82 to US$4.68.

2019Bull2025 Posted - 3 days ago

$PACB I would be concerned if the stock cannot exceed the $2.20 range and stays within this range for a bit

Bidzill Posted - 3 days ago

$PACB Hoping for at least one more good push! 1 hour chart:

Nanu108 Posted - 3 days ago

$PACB I'm out.

FaizyShay23 Posted - 3 days ago

These are the current results for my watch list: Yesterday, the closing price of $FFIE was $0.3660. and went till $0.9800 today Yesterday, the closing price of $PEGY was $0.0667. and went till $0.1175 today Yesterday, the closing price of $SINT was $0.701. and went till $0.2280 today Yesterday, the closing price of $PACB was $2.24. and went till $2.50 today Yesterday, the closing price of $PLUG was $3.57. and went till $3.80 today

Analyst Ratings

Morgan Stanley	Equal-Weight	May 15, 24
Piper Sandler	Neutral	May 13, 24
Barclays	Equal-Weight	May 10, 24
JP Morgan	Neutral	Apr 22, 24
Goldman Sachs	Neutral	Apr 19, 24
Bernstein	Outperform	Apr 18, 24
Goldman Sachs	Neutral	Apr 18, 24
Scotiabank	Sector Outperform	Apr 18, 24
TD Cowen	Buy	Apr 17, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Van Oene Mark	See Remarks See Remarks	Jan 09	Sell	7.773	31,012	241,056	910,171	01/10/24
Kim Susan G.	See Remarks See Remarks	Sep 29	Sell	8.437	19,257	162,471	306,085	09/29/23
Eidel Jeff	See Remarks See Remarks	Aug 17	Sell	10.597	25,936	274,844	444,666	08/18/23
Farmer Michele	See Remarks See Remarks	May 18	Sell	12.59	5,165	65,027	107,577	05/19/23
Kim Susan G.	See Remarks See Remarks	Feb 17	Sell	10.271	907	9,316	162,581	02/22/23
HENRY CHRISTIAN O	See Remarks See Remarks	Feb 17	Sell	10.271	1,530	15,715	642,021	02/22/23
Van Oene Mark	See Remarks See Remarks	Jan 10	Sell	9.534	26,722	254,768	640,808	01/11/23
Kim Susan G.	See Remarks See Remarks	Sep 29	Sell	5.614	12,968	72,802	163,488	10/03/22
MOHR MARSHALL	Director Director	Jun 10	Option	1.83	35,000	64,050	60,000	06/13/22
Farmer Michele	See Remarks See Remarks	May 18	Sell	5.547	3,573	19,819	60,354	05/20/22
ORDONEZ KATHY	Director Director	Feb 16	Sell	11.5	3,280	37,720	18,595	02/17/22
MOHR MARSHALL	Director Director	Jan 14	Option	3.57	25,000	89,250	25,000	01/19/22
Van Oene Mark	Chief Operating Offi.. Chief Operating Officer	Jan 11	Sell	14.23	41,480	590,260	293,520	01/13/22
Fromen Peter	Chief Commercial Off.. Chief Commercial Officer	Jan 11	Sell	14.3	19,720	281,996	140,280	01/13/22
Ericson William W.	Director Director	May 26	Option	6.21	37,500	232,875	37,500	05/26/21
Hunkapiller Michael	Director Director	Feb 26	Option	6.27	605,804	3,798,391	1,187,782	02/26/21
Hunkapiller Michael	Director Director	Feb 26	Sell	34.83	605,804	21,100,153	848,405	02/26/21
ORDONEZ KATHY	Director Director	Feb 18	Option	5.18	185,879	962,853	242,646	02/18/21
ORDONEZ KATHY	Director Director	Feb 18	Sell	48.35	220,771	10,674,278	21,875	02/18/21
LIVINGSTON RANDALL S	Director Director	Feb 17	Option	4.98	67,500	336,150	67,500	02/17/21
LIVINGSTON RANDALL S	Director Director	Feb 17	Sell	48.07	67,500	3,244,725		02/17/21
Botstein David	Director Director	Feb 17	Option	4.58	160,000	732,800	160,000	02/17/21
Botstein David	Director Director	Feb 17	Sell	49.85	160,000	7,976,000		02/17/21
Hunkapiller Michael	Director Director	Jan 27	Option	6.14	125,406	769,993	973,811	01/27/21
Hunkapiller Michael	Director Director	Jan 27	Sell	36.53	125,406	4,581,081	848,405	01/27/21
Hunkapiller Michael	Director Director	Jan 22	Option	4.21	574,594	2,419,041	999,262	01/22/21
Hunkapiller Michael	Director Director	Jan 22	Sell	37.87	624,404	23,646,179	848,405	01/22/21
Hunkapiller Michael	Director Director	Dec 23	Option	4.72	700,000	3,304,000	1,262,666	12/23/20
Hunkapiller Michael	Director Director	Dec 23	Sell	23.88	700,000	16,716,000	898,215	12/23/20